Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655908 | 0.78 | AOC3 (0.34) | MTNR1AHTTCTNNB1WNT3AMEN1 | |
| SCHEMBL668079 | 0.76 | NPC1 (0.36) | MTNR1ACTNNB1WNT3AMEN1KMT2A | |
| SCHEMBL19380525 | 0.75 | TSHR (0.42) | MTNR1AHTTCTNNB1WNT3AKDM4E | |
| Hydrazine SCHEMBL14688080 | 0.73 | KDM4E (0.43) | MTNR1AHTTCTNNB1WNT3AKDM4E | |
| SCHEMBL19380488 | 0.73 | MLYCD (0.39) | MTNR1AHTTKDM4EALDH1A1BRCA1 | |
| SCHEMBL77894 | 0.73 | KDM4E (0.44) | MTNR1AHTTCTNNB1WNT3AKDM4E | |
| SCHEMBL19380526 | 0.73 | KDM4E (0.49) | MTNR1AHTTCTNNB1WNT3AMEN1 | |
| SCHEMBL5172008 | 0.72 | MTNR1A (0.32) | MTNR1ALMNATSHRAOC3 | |
| SCHEMBL668910 | 0.72 | MTNR1A (0.40) | MTNR1AALDH1A1LMNAHDAC3HDAC4 | |
| SCHEMBL668928 | 0.72 | ATM (0.40) | MTNR1AHTTCTNNB1WNT3AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342440-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System | INTREXON CORP (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3219204-A1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | Intrexon Corporation (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2460786-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2292088-B1 | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system | INTREXON CORP (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20120185954-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression | INTREXON CORPORATION (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2460786-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342440-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System | NR2E3, NR1H4, NR5A2 | MTNR1A 263/4885HTT 3664/4885CTNNB1 4275/4885 |
| US-20120185954-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression | NR2E3, NR5A2, NCOA3 | MTNR1A 279/4885HTT 3643/4885CTNNB1 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.